Due to the fact that AHR is a transcription factor and ELAVL1 is a post-transcriptional gene expression regulator, this interaction and its changes involve many different cell mechanisms involved in cytoprotection, migration, overall viability of the cell, and most importantly to PC treatment chemoresistance. Here, ELAVL1 is linked to pachyonychia congenita.